Pure Global AI
NCT06391034Not yet recruiting

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer Undergoing Radiation Therapy
Robert Bok, MD, PhDPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Prostate Cancer
Drug/Device/Intervention
hyperpolarized pyruvate +/-urea (13C/15N)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Robert Bok, MD, PhD
Funder
University of California, San Francisco
Location
San Francisco, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2024
End date
Jun 30, 2032
Enrollment
161 participants
Primary outcome

Signal-to-noise ratio (Part 1),Mean HP 13C-pyruvate to lactate metabolic rate of conversion (kPL) over time (Part 2A),Mean HP 13C-pyruvate to glutamate metabolic rate of conversion (kPG) over time (Part 2A),Mean change in on-treatment kPL over time (Part 2B),Mean change in on-treatment kPG over time (Part 2B),Mean kPL at time of biochemical failure (Part 3),Mean kPG at time of biochemical failure (Part 3)

Summary

This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea
 (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have
 received radiation therapy for prostate cancer.

ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06391034
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06391034 through Pure Global AI's free database. This Phase 2 trial is sponsored by Robert Bok, MD, PhD and is currently Not yet recruiting. The study focuses on Prostate Cancer. Target enrollment is 161 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.